Amyloidosis News and Research

RSS
Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.
Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Study shows how tafamidis drug works against amyloid disease

Study shows how tafamidis drug works against amyloid disease

FDA advisory committee votes in favor of Pfizer's tafamidis meglumine

FDA advisory committee votes in favor of Pfizer's tafamidis meglumine

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam first quarter revenues decrease to $20.6 million

Alnylam first quarter revenues decrease to $20.6 million

Nephros granted rights to market products based on Medica's Medisulfone ultrafiltration technology

Nephros granted rights to market products based on Medica's Medisulfone ultrafiltration technology

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Positive effect of tafamidis on neurological degeneration

Positive effect of tafamidis on neurological degeneration

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

U.S. FDA accepts Pfizer's tafamidis NDA for treatment of TTR-FAP

U.S. FDA accepts Pfizer's tafamidis NDA for treatment of TTR-FAP

Two studies demonstrate preliminary success of CyBorD in AL amyloidosis

Two studies demonstrate preliminary success of CyBorD in AL amyloidosis

CyBorD regimen shows promise against AL amyloidosis

CyBorD regimen shows promise against AL amyloidosis

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

New cERD method can detect RNAi activity in biological fluids

New cERD method can detect RNAi activity in biological fluids

Mayo Clinic Healthy Heart For Life! to be available online on Jan. 31

Mayo Clinic Healthy Heart For Life! to be available online on Jan. 31

Alnylam receives U.S. patent allowance for LNP platform

Alnylam receives U.S. patent allowance for LNP platform

Alnylam sues Tekmira over LNP-formulated siRNA molecules

Alnylam sues Tekmira over LNP-formulated siRNA molecules

Excess salt stimulates production of adrenalin and causes hypertension

Excess salt stimulates production of adrenalin and causes hypertension

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR